Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
18.84
-0.29 (-1.52%)
At close: May 13, 2026, 4:00 PM EDT
18.97
+0.13 (0.69%)
Pre-market: May 14, 2026, 8:08 AM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $730.80M in the quarter ending March 31, 2026, a decrease of -1.89%. This brings the company's revenue in the last twelve months to $2.18B, down -2.20% year-over-year. In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth.
Revenue (ttm)
$2.18B
Revenue Growth
-2.20%
P/S Ratio
0.91
Revenue / Employee
$2,615,789
Employees
835
Market Cap
1.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.33M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 509.86M |
| Aurinia Pharmaceuticals | 298.30M |
| Ascentage Pharma Group International | 82.08M |
| Intellia Therapeutics | 66.09M |
| Ocular Therapeutix | 52.04M |
| Stoke Therapeutics | 32.08M |
| Generate Biomedicines | 30.30M |
| Taysha Gene Therapies | 7.47M |
SRPT News
- 15 hours ago - Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Business Wire
- 7 days ago - Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year - TheFly
- 7 days ago - Sarepta Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments - Business Wire
- 21 days ago - Sarepta Therapeutics to Announce First Quarter 2026 Financial Results - Business Wire
- 27 days ago - Roche decision could hurt Sarepta in U.S., says H.C. Wainwright - TheFly
- 5 weeks ago - Sarepta price target raised to $19 from $18 at RBC Capital - TheFly
- 6 weeks ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire